Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Gary Guishan Xiao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5078996176. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
2
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 6 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers

Papers 24

  1. NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Co-author DOI 10.1016/j.celrep.2024.115226↗
  2. Serum microRNA-24-based nomogram predicts prognosis for patients with resected pancreatic cancer. Last author DOI 10.1038/s41598-024-82369-9↗
  3. NAMPT Modulates Gemcitabine Resistance in Pancreatic Cancer via the p53 Signaling Pathway. Co-author DOI 10.1097/mpa.0000000000002468↗
  4. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. Last author DOI 10.1007/s10620-024-08338-4↗
  5. Targeted inhibition of CHKα and mTOR in models of pancreatic ductal adenocarcinoma: A novel regimen for metastasis. Co-author DOI 10.1016/j.canlet.2024.217280↗
  6. Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer. Last author DOI 10.1016/j.isci.2024.110027↗
  7. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  8. Berberine inhibits the proliferation of pancreatic cancer cells by targeting pancreatic cancer stem cells through regulating EMT signaling pathway Last author DOI 10.32604/biocell.2022.020325↗
  9. Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway. Last author DOI 10.3389/fphar.2022.1068855↗
  10. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. Last author DOI 10.1016/j.phrs.2021.105595↗
  11. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal. Last author DOI 10.1097/mpa.0000000000001920↗
  12. MicroRNAs in Pancreatic Cancer and Chemoresistance. Last author DOI 10.1097/mpa.0000000000001934↗
  13. Bioinformatics Analysis of a Prognostic miRNA Signature and Potential Key Genes in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.641289↗
  14. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  15. Progress on the role of reactive oxygen species-mediated tumor microenvironment in pancreatic cancer. Last author PMID 33903881↗
  16. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  17. Targeting Serotonin System in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001417↗
  18. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  19. Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer. Last author DOI 10.1186/s12935-020-01550-y↗
  20. Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition. Co-author DOI 10.1097/mpa.0000000000001321↗
  21. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗
  22. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. Last author DOI 10.1186/s40364-016-0074-3↗
  23. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Last author DOI 10.1186/2162-3619-2-18↗
  24. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Last author DOI 10.1097/mpa.0b013e318236f022↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianzhou Liu · 9 shared papers, 2016–2025 · strength 1.62
  2. Junchao Guo · 7 shared papers, 2020–2025 · strength 1.29
  3. Vay Liang W. Go · 8 shared papers, 2012–2025 · strength 1.07
  4. Wenchao Xu · 4 shared papers, 2024–2025 · strength 0.89
  5. Xufeng Tao · 5 shared papers, 2021–2022 · strength 0.82
  6. Yongwei Sun · 6 shared papers, 2019–2025 · strength 0.79
  7. Zhigang Zhang · 6 shared papers, 2019–2024 · strength 0.66
  8. Minwei Yang · 4 shared papers, 2020–2025 · strength 0.61
  9. Qiaofei Liu · 3 shared papers, 2020–2025 · strength 0.54
  10. Ge Gao · 4 shared papers, 2019–2024 · strength 0.53
  11. Junchao Guo · 3 shared papers, 2020–2025 · strength 0.48
  12. Jing Li Huang · 3 shared papers, 2016–2024 · strength 0.43
  13. Li Zhou · 3 shared papers, 2020–2024 · strength 0.42
  14. Qing Li · 4 shared papers, 2019–2023 · strength 0.40
  15. Li-Peng Hu · 4 shared papers, 2019–2023 · strength 0.40
  16. Shu‐Heng Jiang · 4 shared papers, 2019–2023 · strength 0.40
  17. Jing Huang · 2 shared papers, 2021–2025 · strength 0.38
  18. Dong Shang · 2 shared papers, 2021–2024 · strength 0.34
  19. Zhiyong Liang · 2 shared papers, 2020–2025 · strength 0.34
  20. Bolun Jiang · 2 shared papers, 2020–2024 · strength 0.33
  21. Qin Yang · 3 shared papers, 2019–2023 · strength 0.32
  22. Yue Pan · 2 shared papers, 2021 · strength 0.27
  23. Jiajia Xu · 1 shared paper, 2025 · strength 0.25
  24. Qian Zhang · 1 shared paper, 2025 · strength 0.23
  25. Tianli Zhang · 1 shared paper, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.